6.49MMarket Cap-0.45P/E (TTM)
0.360High0.360Low316Volume0.360Open0.361Pre Close113.76Turnover0.00%Turnover RatioLossP/E (Static)18.02MShares3.16352wk High2.08P/B4.72MFloat Cap0.26052wk Low--Dividend TTM13.12MShs Float15.550Historical High--Div YieldTTM0.00%Amplitude0.260Historical Low0.360Avg Price1Lot Size
bioAffinity Technologies Stock Forum
Can bioAffinity's $4M Cost-Cutting Plan Transform Its Cancer Detection Business?
bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic
Wednesday, 22nd January at 8:00 am
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that the Australian Patent Office (IP Australia), has accepted bioAffinity's patent application for the method...
bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic
bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung
Monday, 13th January at 8:00 am
bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today reported the results of the Company's CyPath® Lung pilot marketing program using Texas for our beta launch with sales of more than 600 tests delivered in...
No comment yet